Ascendis Pharma is set to report its Q2 2025 earnings after market close today. Analysts estimate the company will report $92.74 million in revenue, representing a 79.54% year-over-year increase, and an earnings per share loss of $1.56. Additionally, Ascendis Pharma and Royalty Pharma have entered into a $150 million royalty funding agreement. Ascendis Pharma ADRs fell 15.2% pre-market on lower-than-expected Q2 earnings. Meanwhile, Asana's revenue outlook has fallen short, leading to a 13% decline in its share price. For Q3 fiscal 2025, Asana expects revenues of $180 million to $181 million, representing growth of 8% to 9% year-over-year, and a non-GAAP loss from operations of $18 million to $19 million.